{"name":"Polichem S.A.","slug":"polichem-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"amorolfine 5%","genericName":"amorolfine 5%","slug":"amorolfine-5","indication":"Onychomycosis","status":"phase_3"},{"name":"Finasteride 0.25%","genericName":"Finasteride 0.25%","slug":"finasteride-0-25","indication":"Other","status":"phase_1"},{"name":"P-3074 Vehicle","genericName":"P-3074 Vehicle","slug":"p-3074-vehicle","indication":"Other","status":"phase_3"},{"name":"vehicle of P-3058 10%","genericName":"vehicle of P-3058 10%","slug":"vehicle-of-p-3058-10","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"P-3058","genericName":"P-3058","slug":"p-3058","indication":"Type 2 diabetes","status":"phase_3"},{"name":"P-3074","genericName":"P-3074","slug":"p-3074","indication":"Type 2 diabetes","status":"phase_3"},{"name":"P-3058 10%","genericName":"P-3058 10%","slug":"p-3058-10","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"P-3073","genericName":"P-3073","slug":"p-3073","indication":"Relapsing multiple sclerosis","status":"phase_3"}]}],"pipeline":[{"name":"amorolfine 5%","genericName":"amorolfine 5%","slug":"amorolfine-5","phase":"phase_3","mechanism":"Amorolfine is an antifungal agent that inhibits the growth of fungi by interfering with the synthesis of ergosterol, an essential component of fungal cell membranes.","indications":["Onychomycosis"],"catalyst":""},{"name":"P-3058","genericName":"P-3058","slug":"p-3058","phase":"phase_3","mechanism":"P-3058 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"P-3074","genericName":"P-3074","slug":"p-3074","phase":"phase_3","mechanism":"P-3074 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Finasteride 0.25%","genericName":"Finasteride 0.25%","slug":"finasteride-0-25","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"P-3058 10%","genericName":"P-3058 10%","slug":"p-3058-10","phase":"phase_3","mechanism":"P-3058 10% is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Type 2 diabetes"],"catalyst":""},{"name":"P-3073","genericName":"P-3073","slug":"p-3073","phase":"phase_3","mechanism":"P-3073 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"P-3074 Vehicle","genericName":"P-3074 Vehicle","slug":"p-3074-vehicle","phase":"phase_3","mechanism":"P-3074 Vehicle is a drug that acts as a vehicle for other pharmaceutical compounds.","indications":[],"catalyst":""},{"name":"vehicle of P-3058 10%","genericName":"vehicle of P-3058 10%","slug":"vehicle-of-p-3058-10","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQRFFma2hYVF9BVUV1ZkVMWHo0X1otRURsemk4VEFSWHUwWloxR0l1enk4eE9Ya2lpdHFvZEJGRmpTMlhTUW5qZk45MGVOQV9XS050em9weV9lVEdmV2pQRWlZbko4R3ZiUXQzSUhHdmFlMzVOUjVvTVZLYy1zemR4OXB4Tl8zblJhdjVZaGJmMGVUZXNyMk1NZ2N4U0lzQmkxb1h2WUJvbjlQanVaaVpWOElFQnhIS2FXQVVSRDBFbzVucnRvTmFNTGlvNkgyUWdEM2NuT3V4RWs5cVpYcDJwekdxbVM2N0ZlVkpJ?oc=5","date":"2021-02-25","type":"trial","source":"European Medical Journal","summary":"Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab - European Medical Journal","headline":"Clinical Considerations Based On 5-Year Efficacy and Safety Data for the IL-23p19 Inhibitor Tildrakizumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPSlFVbkRhNUJlc1BhNlUyUGVZTUtHdkg3WEVoZk5nNkFhS0JBcWd3N21VSW5wcVBYNHh5VE5uR2k4bXJ1SVg5XzJ6dWNjMmluSXpJVzZvX3R4Wm5UTndRenl0dEE5WF9JLTA5a3FIZ1M2VnJkTUZJZUxFeTZ0V0IxM2tRdDFkUVlGbXZjMzExUEhjMDVld2tBdzg0MVVuUzlST0VUQjE1VUtCaUJG?oc=5","date":"2015-11-30","type":"deal","source":"Genetic Engineering and Biotechnology News","summary":"Almirall Expands in Dermatology, Buying Poli Group for $386M+ - Genetic Engineering and Biotechnology News","headline":"Almirall Expands in Dermatology, Buying Poli Group for $386M+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBFdmR2WXdvMXAtVFBnT2JoeXdhMWtXeW8zcVRMcm9RWlB1U3psaVVSNDc0emdTYnVRNFdBeFFnT3M2MDhDZ1JrQVF0cnY3OHRDN2Z5ZWlMbzZ1VThObHl1c3B1R0hxYkRXajJyak5raDk5SV83RG5CdQ?oc=5","date":"2015-11-30","type":"deal","source":"Pharmafile","summary":"Almirall to acquire Poli Group’s skin drugs - Pharmafile","headline":"Almirall to acquire Poli Group’s skin drugs","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"phase_3":7,"phase_1":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}